First-in-Human Study of ICT01 in Patients With Advanced Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Hematopoietic/Lymphoid Cancer
- Solid Tumor, Adult
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Patients will be assigned to a dose level of ICT01 at the time of their enrollmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04243499
- Collaborators
- Not Provided
- Investigators
- Study Director: Paul Frohna, MD, PhD ImCheck Therapeutics
Get Well Soon